A public-private partnership between ARPA-H and VentureWell in support of the ARPANET-H nationwide health innovation network. Website is maintained by VentureWell staff.
Portal Biotechnologies is excited to be partnering with Bayer Co.Lab for a special cocktail reception with the ARPA-H Investor Catalyst Hub and Massachusetts General Brigham Gene and Cell Therapy Institute (GCTI) on Wednesday, May 22, 5-7 p.m., with doors opening at 4:30 p.m. Please join Portal Founder and CEO Armon Sharei; Chelsea Schiller, Director, ARPA-H Catalyst Hub; Roger Hajjar, Director, GCTI; other members of the Cambridge cell and gene therapy innovation community; and more!